We first used the web-based tool Kaplan-Meier plotter (50) to assess the correlation between RET mRNA expression and overall survival (OS) and relapse-free survival (RFS) in a cohort of ER+ breast cancer patients receiving endocrine treatment in the primary setting. The gene discussed is RET; the disease is breast carcinoma.